← All trials
NCT03220178
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2017
- Primary completion
- Jun 30, 2021
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 960
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Palleos Healthcare GmbHLead sponsor
- PfizerCollaborator
- AGO GermanyCollaborator
- CANKADOCollaborator
- Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.Collaborator
- Palleos Healthcare GmbHStudy director
- WSG WOMEN´S HEALTHCARE STUDY GROUPCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.